Taysha Gene Therapies Approves Share Increase Amendment

Taysha Gene Therapies ( (TSHA) ) has shared an announcement.

On June 2, 2025, Taysha Gene Therapies, Inc. held its annual meeting of stockholders where an amendment to increase the authorized number of shares of common stock from 400,000,000 to 700,000,000 was approved. Additionally, two directors were elected, and Deloitte & Touche LLP’s appointment as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. These decisions reflect the company’s strategic focus on expanding its capital structure and solidifying its governance framework.

The most recent analyst rating on (TSHA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Taysha Gene Therapies stock, see the TSHA Stock Forecast page.

Spark’s Take on TSHA Stock

According to Spark, TipRanks’ AI Analyst, TSHA is a Neutral.

Taysha Gene Therapies’ stock is moderately rated due to positive clinical and regulatory progress for TSHA-102, which is offset by weak financial performance and a poor valuation. The technical indicators and recent corporate events provide some optimism, but financial restructuring is crucial for long-term stability.

To see Spark’s full report on TSHA stock, click here.

More about Taysha Gene Therapies

Taysha Gene Therapies, Inc. operates in the biotechnology industry, focusing on developing and delivering gene therapy solutions for the treatment of monogenic diseases of the central nervous system. The company aims to address significant unmet medical needs with its innovative therapies.

Average Trading Volume: 3,205,184

Technical Sentiment Signal: Buy

Current Market Cap: $728.4M

Find detailed analytics on TSHA stock on TipRanks’ Stock Analysis page.